Targeting antibodies to the cytoplasm

mAbs

Volumn 3, Issue 1, 2011, Pages 3-16

  Marschall, Andrea L J ^a   Frenzel, André ^a   Schirrmann, Thomas ^a   Schüngel, Manuela ^a   Dübel, Stefan ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Cell penetrating peptides; Cytosolic delivery; Intrabodies; Intracellular antibody; Intracellular delivery; Live cell imaging; Profection; Protein transduction domains; Protein transfection; Transbodies

Indexed keywords

ANTIBODY; CELL PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY STRUCTURE; CARBOXY TERMINAL SEQUENCE; CELL COMPARTMENTALIZATION; CYTOPLASM; CYTOSOL; DISULFIDE BOND; DNA TRANSFECTION; ELECTRON MICROSCOPY; INTRACELLULAR SIGNALING; MEMBRANE PERMEABILITY; PHOTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TRANSPORT; REVIEW; SECRETORY PATHWAY; STATIC ELECTRICITY; TWO HYBRID SYSTEM;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; CYTOPLASM; ENDOCYTOSIS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN FOLDING; PROTEIN TRANSPORT; RECOMBINANT PROTEINS;

EID: 78651396493     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.1.14110     Document Type: Review

References (209)

1. Kitano H. Systems biology: A brief overview. Science 2002; 295:1662-4.
2. Berglund L, Bjorling E, Jonasson K, Rockberg J, Fagerberg L, Al-Khalili Szigyarto C, et al. A wholegenome bioinformatics approach to selection of antigens for systematic antibody generation. Proteomics 2008; 8:2832-9.
3. Taussig MJ, Stoevesandt O, Borrebaeck CA, Bradbury AR, Cahill D, Cambillau C, et al. ProteomeBinders: Planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods 2007; 4:13-7.
4. Mersmann M, Meier D, Mersmann J, Helmsing S, Nilsson P, Graslund S, et al. Towards proteome scale antibody selections using phage display. N Biotechnol 2010; 27:118-28.
5. Pershad K, Pavlovic JD, Graslund S, Nilsson P, Colwill K, Karatt-Vellatt A, et al. Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display. Protein Eng Des Sel 2010; 23:279-88.
6. Böldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 2007; 11:54-70. (Pubitemid 46439625)
7. Dübel S. Antibody production, human, recombinant. In: Flickinger MC, Ed. Encyclopedia of industrial biotechnology, bioprocess, bioseparation and cell technology. Wiley VCH 2010; 1:351-65.
8. Gawlitta W, Osborn M, Weber K. Coiling of intermediate filaments induced by microinjection of a vimentin-specific antibody does not interfere with locomotion and mitosis. Eur J Cell Biol 1981; 26:83-90. (Pubitemid 12172689)
9. Lin JJ, Feramisco JR. Disruption of the in vivo distribution of the intermediate filaments in fibroblasts through the microinjection of a specific monoclonal antibody. Cell 1981; 24:185-93.
10. Blose SH, Meltzer DI, Feramisco JR. 10 nm filaments are induced to collapse in living cells microinjected with monoclonal and polyclonal antibodies against tubulin. J Cell Biol 1984; 98:847-58.
11. Warn RM, Flegg L, Warn A. An investigation of microtubule organization and functions in living Drosophila embryos by injection of a fluorescently labeled antibody against tyrosinated alpha-tubulin. J Cell Biol 1987; 105:1721-30.
12. Kallajoki M, Harborth J, Weber K, Osborn M. Microinjection of a monoclonal antibody against SPN antigen, now identified by peptide sequences as the NuMA protein, induces micronuclei in PtK2 cells. J Cell Sci 1993; 104:139-50. (Pubitemid 23073176)
13. Dubel S, Stoevesandt O, Taussig MJ, Hust M. Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 2010; 28:333-9.
14. Stocks M. Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol 2005; 9:359-65. (Pubitemid 41019681)
15. Kirkpatrick RB, Ganguly S, Angelichio M, Griego S, Shatzman A, Silverman C, et al. Heavy-chain dimers as well as complete antibodies are efficiently formed and secreted from Drosophila via a bip-mediated pathway. J Biol Chem 1995; 270:19800-5.
16. Mayer M, Kies U, Kammermeier R, Buchner J. BiP and PDI cooperate in the oxidative folding of antibodies in vitro. J Biol Chem 2000; 275:29421-5. (Pubitemid 32043816)
17. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994; 269:23931-6.
18. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA 1995; 92:3137-41.
19. Kontermann R. Intrabodies as therapeutic agents. Methods 2004; 34:163-70.
20. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 2005; 168:863-8.
21. Strebe N, Guse A, Schungel M, Schirrmann T, Hafner M, Jostock T, et al. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. J Immunol Methods 2008; 341: 30-40.
22. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9-18.
23. Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology 1995; 13:1110-5.
24. Auf der Maur A, Tissot K, Barberis A. Antigen-independent selection of intracellular stable antibody frameworks. Methods 2004; 34:215-24.
25. Visintin M, Quondam M, Cattaneo A. The intracellular antibody capture technology: Towards the highthroughput selection of functional intracellular antibodies for target validation. Methods 2004; 34:200-14. (Pubitemid 39092814)
26. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Biotechnology 1994; 12:396-9.
27. Tanaka T, Rabbitts TH. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J 2003; 22:1025-35.
28. Conrad U, Manteuffel R. Immunomodulation of phytohormones and functional proteins in plant cells. Trends Plant Sci 2001; 6:399-402.
29. Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008; 343-73.
30. Alting-Mees MA, Risseeuw EP, Liu E, Desautels M, Crosby WA, Hemmingsen SM. Intracellular expression of recombinant antibody fluorescent protein fusions for localization of target antigens in Schizosaccharomyces pombe. Methods Mol Biol 2006; 313:97-105.
31. Tanaka T, Rabbitts TH. Functional Intracellular Antibody Fragments Do Not Require Invariant Intradomain Disulfide Bonds. J Mol Biol 2008; 794-57.
32. Tse E, Lobato MN, Forster A, Tanaka T, Chung GTY, Rabbitts TH. Intracellular antibody capture technology: Application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol 2002; 85-94.
33. Visintin M, Settani G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): Towards a consensus sequence for intracellular antibodies. J Mol Biol 2002; 317:73-83. (Pubitemid 34722200)
34. Tanaka T, Chung GTY, Forster A, Lobato MN, Rabbitts TH. De novo production of diverse intracellular antibody libraries. Nuc Acids Res 2003; 31:23.
35. Stocks M. Intrabodies: Production and promise. Drug Discovery Today 2004; 9:960-6.
36. Lee PA, Tullman-Ercek D, Georgiou G. The bacterial twin-arginine translocation pathway. Annu Rev Microbiol 2006; 373-95.
37. Fisher A, DeLisa MP. Efficient isolation of soluble intracellular single-chain antibodies using the twinarginine translocation machinery. J Mol Biol 2009; 385:299-311.
38. Shaki-Loewenstein S, Zfania R, Hyland S, Wels WS, Benhar I. A universal strategy for stable intracellular antibodies. J Immunol Meth 2005; 303:19-39.
39. Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 1998; 17:2445-56.
40. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tatmediated LTR transactivation and HIV-1 infection vy anti-Tat single chain intrabodies. EMBO J 1995; 14:1542-51.
41. Zheng L, Baumann U, Reymond JL. Production of a functional catalytic antibody ScFv-NusA fusion protein in bacterial cytoplasm. J Biochem 2003; 133:577-81.
42. Jannot CB, Hynes NE. Characterization of scFv-421, a single-chain antibody targeted to p53. Biochem Biophys Res Commun 1997; 230:242-6.
43. Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 1999; 1668-74.
44. Nallamsetty S, Waugh DS. Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. Protein Expr Purif 2006; 45:175-82.
45. Esposito D, Chatterjee DK. Enhancement of soluble protein expression through the use of fusion tags. Curr Opin Biotechnol 2006; 17:353-8. (Pubitemid 44163452)
46. Gräslund S. Protein production and purification. Nat Meth 2008; 5:135-46.
47. Cardinale A, Filesi I, Biocca S. Aggresome formation by anti-Ras intracellular scFv fragments - the fate of the antigen antibody complex. Eur J Biochem 2001; 268-77. (Pubitemid 32862656)
48. Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol 1998; 280:117-27.
49. Bach H, Mazor Y, Shaky S, Shoham-Lev A, Berdichevsky Y, Gutnick DL, et al. Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies. J Mol Biol 2001; 312:79-93.
50. Weill CO, Biri S, Adib A, Erbacher P. A practical approach for intracellular protein delivery. Cytotechnology 2008; 41-8.
51. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989; 243:375-8.
52. Debs RJ, Freedman LP, Edmunds S, Gaensler KL, Duzgunes N, Yamamoto KR. Regulation of gene-expression invivo by liposome-mediated delivery of a purified transcription factor. J Biol Chem 1990; 265:10189-92. (Pubitemid 120000961)
53. Kato K, Nakanishi M, Kaneda Y, Uchida T, Okada Y. Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. J Biol Chem 1991; 266:3361-4. (Pubitemid 21909217)
54. Baubonis W, Sauer B. Genomic targeting with purified Cre recombinase. Nucleic Acids Res 1993; 21:2025-9. (Pubitemid 23160716)
55. Gao X, Huang L. Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes. Nucleic Acids Res 1993; 21:2867-72. (Pubitemid 23220438)
56. Chu CJ, Dijkstra J, Lai MZ, Hong K, Szoka FC. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm Res 1990; 7:824-43. (Pubitemid 20332534)
57. Nair S, Zhou X, Huang L, Rouse BT. Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J Immunol Methods 1992; 237-43.
58. Lin MF, DaVolio J, Garcia R. Cationic liposomemediated incorporation of prostatic acid phosphatase protein into human prostate carcinoma cells. Biochem Biophys Res Commun 1993; 192:413-9.
59. Sells MA, Li J, Chernoff J. Delivery of protein into cells using polycationic liposomes. Biotechniques 1995; 19:72-6.
60. Lee KD, Oh YK, Portnoy DA, Swanson JA. Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem 1996; 271:7249-52.
61. Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C. Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 1998; 72:7653-8.
62. Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 2001; 276:35103-10.
63. Kessels MM, Qualmann B. Syndapins integrate N-WASP in receptor-mediated endocytosis. EMBO J 2002; 21:6083-94.
64. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100:13791-6.
65. Gil GA, Bussolino DF, Portal MM, Pecchio AA, Renner ML, Borioli GA, et al. c-Fos activated phospholipid synthesis is required for neurite elongation in differentiating PC12 cells. Mol Biol Cell 2004; 15:1881-94.
66. +-ATPase requires ERK-dependent translocation of protein kinase Calpha. J Biol Chem 2005; 280:8705-13.
67. Taieb F, Nougayrede JP, Watrin C, Samba-Louaka A, Oswald E. Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway. Cell Microbiol 2006; 8:1910-21.
68. Hostetter DR, Loeb CR, Chu F, Craik CS. Hip is a pro-survival substrate of granzyme B. J Biol Chem 2007; 282:27865-74.
69. Lofgren S, Fernando MR, Xing KY, Wang Y, Kuszynski CA, Ho YS, et al. Effect of thioltransferase (glutaredoxin) deletion on cellular sensitivity to oxidative stress and cell proliferation in lens epithelial cells of thioltransferase knockout mouse. Invest Ophthalmol Vis Sci 2008; 49:4497-505.
70. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA 2009; 106:20051-6.
71. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010; 30:2967-78.
72. Tinsley JH, Hawker J, Yuan Y. Efficient protein transfection of cultured coronary venular endothelial cells. Am J Physiol Heart Circ Physiol 1998:1873-8.
73. Tinsley JH, Zawieja DC, Wu MH, Ustinova EE, Xu W, Yuan SY. Protein transfection of intact microvessels specifically modulates vasoreactivity and permeability. J Vasc Res 2001; 444-52.
74. waf1 pathway in A431 cells. Genes Cells 2003; 8:995-1003.
75. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115:575-85.
76. Dalkara D, Zuber G, Behr JP. Intracytoplasmic delivery of anionic proteins. Mol Ther 2004; 9:964-9.
77. Heerssen HM, Pazyra MF, Segal RA. Dynein motors transport activated Trks to promote survival of target-dependent neurons. Nat Neurosci 2004; 7:596-604.
78. Didenko VV, Ngo H, Baskin DS. Polyethyleneimine as a transmembrane carrier of fluorescently labeled proteins and antibodies. Anal Biochem 2005; 168-73.
79. Laloraya M, Davoodi-Semiromi A, Kumar GP, McDuffie M, She JX. Impaired Crkl expression contributes to the defective DNA binding of Stat5b in nonobese diabetic mice. Diabetes 2006; 55:734-41.
80. Cortes C, Rzomp KA, Tvinnereim A, Scidmore MA, Wizel B. Chlamydia pneumoniae inclusion membrane protein Cpn0585 interacts with multiple Rab GTPases. Infect Immun 2007; 75:5586-96.
81. Geel TM, Meiss G, van der Gun BT, Kroesen BJ, de Leij LF, Zaremba M, et al. Endonucleases induced TRAIL-insensitive apoptosis in ovarian carcinoma cells. Exp Cell Res 2009; 315:2487-95.
82. Weill CO, Biri S, Erbacher P. Cationic lipid-mediated intracellular delivery of antibodies into live cells. Biotechniques 2008; 44:7-9.
83. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 2004; 279:17957-62.
84. Nagai J, Christensen EI, Morris SM, Willnow TE, Cooper JA, Nielsen R. Mutually dependent localization of megalin and Dab2 in the renal proximal tubule. Am J Physiol Renal Physiol 2005; 289:569-76.
85. Takami T, Terai S, Yokoyama Y, Tanimoto H, Tajima K, Uchida K, et al. Human homologue of maid is a useful marker protein in hepatocarcinogenesis. Gastroenterology 2005; 128:1369-80.
86. Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 2006; 5:2388-97.
87. Ying M, Chen B, Tian Y, Hou Y, Li Q, Shang X, et al. Nuclear import of human sexual regulator DMRT1 is mediated by importin-beta. Biochim Biophys Acta 2007; 1773:804-13.
88. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, et al. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 2009; 11:10-21.
89. Duerr CU, Zenk SF, Chassin C, Pott J, Gutle D, Hensel M, et al. O-antigen delays lipopolysaccharide recognition and impairs antibacterial host defense in murine intestinal epithelial cells. PLoS Pathog 2009; 5:1000567.
90. Lee Y, Ishii T, Kim HJ, Nishiyama N, Hayakawa Y, Itaka K, et al. Efficient delivery of bioactive antibodies into the cytoplasm of living cells by charge-conversional polyion complex micelles. Angew Chem Int Ed Engl 2010; 49:2552-5.
91. Dalkara D, Chandrashekhar C, Zuber G. Intracellular protein delivery with a dimerizable amphiphile for improved complex stability and prolonged protein release in the cytoplasm of adherent cell lines. J Control Release 2006; 116:353-9.
92. van der Gun BTF, Monami A, Laarmann S, Raskó T, Slaska-Kiss K, Weinhold E, et al. Serum insensitive, intranuclear protein delivery by the multipurpose cationic lipid SAINT-2. J Control Release 2007; 228-38.
93. Lee AL, Wang Y, Ye WH, Yoon HS, Chan SY, Yang YY. Efficient intracellular delivery of functional proteins using cationic polymer core/shell nanoparticles. Biomaterials 2008; 29:1224-32.
94. Jung S, Huh S, Cheon YP, Park S. Intracellular protein delivery by glucose-coated polymeric beads. Chem Commun (Camb) 2009; 7:5003-5.
95. Sanchez-Martin RM, Alexander L, Muzerelle M, Cardenas-Maestre JM, Tsakiridis A, Brickman JM, et al. Microsphere-mediated protein delivery into cells. Chembiochem 2009; 10:1453-6.
96. Tada S, Chowdhury EH, Cho CS, Akaike T. pHsensitive carbonate apatite as an intracellular protein transporter. Biomaterials 2010; 31:1453-9.
97. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
98. Herve F, Ghinea N, Scherrmann JM. CNS Delivery Via Adsorptive Transcytosis. The AAPS Journal 2008; 10:455-72.
99. Triguero D, Buciak JB, Yang J, Pardridge WM. Bloodbrain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 4761-5.
100. Futami J, Kitazoe M, Maeda T, Nukui E, Sakaguchi M, Kosaka J, et al. Intracellular delivery of proteins into mammalian living cells by polyethyleneiminecationization. J Biosci Bioeng 2005; 99:95-103.
101. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 1996; 93:12349-54.
102. Kopatz I, Remy JS, Behr JP. A model for non-viral gene delivery: Through syndecan adhesion molecules and powered by actin. J Gene Med 2004; 6:769-76.
103. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006; 32-45.
104. Behr JP. The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 1997; 51:34-6.
105. Chuck AS, Clarke MF, Palsson BO. Retroviral infection is limited by Brownian motion. Hum Gene Ther 1996; 7:1527-34.
106. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability. Pharm Res 1998; 15:1332-9.
107. Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol 2000; 18:893-5.
108. Ross PC, Hui SW. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther 1999; 6:651-9.
109. Duan Y, Zhang S, Wang B, Yang B, Zhi D. The biological routes of gene delivery mediated by lipid-based non-viral vectors. Expert Opin Drug Deliv 2009; 6:1351-61.
110. Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92:7739-43.
111. Plank C, Schillinger U, Scherer F, Bergemann C, Remy JS, Krötz, F, et al. The magnetofection method: Using magnetic force to enhance gene delivery. Biol Chem 2003; 737-47.
112. Rejman J, Bragonzi A, Conese M. Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005; 12:468-74.
113. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004; 377:159-69.
114. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 603-12.
115. Bally MB, Harvie P, Wong FMP, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 1999; 38:291-315.
116. Futami J, Yamada H. Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery. Curr Pharm Biotechnol 2008; 9:180-4.
117. Ye D, Xu D, Singer AU, Juliano RL. Evaluation of strategies for the intracellular delivery of proteins. Pharm Res 2002; 19:1302-9.
118. Prochiantz A, Joliot A. Can transcription factors function as cell-cell signalling molecules? Nat Rev Mol Cell Biol 2003; 4:814-9.
119. Bird CH, Sun J, Ung K, Karambalis D, Whisstock JC, Trapani JA, et al. Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 2005; 25:7854-67.
120. Prochiantz A. Messenger proteins: Homeoproteins, TAT and others. Curr Opin Cell Biol 2000; 12:400-6.
121. Fischer PM. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: Progress 2001-2006. Med Res Rev 2007; 27:755-95.
122. Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration by transportan. Faseb J 1998; 12:67-77.
123. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007; 8:848-66.
124. Gump JM, June RK, Dowdy SF. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J Biol Chem 2010; 285:1500-7.
125. Nakase I, Takeuchi T, Tanaka G, Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev 2008; 60:598-607.
126. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 2003; 28:145-51.
127. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003; 278:35109-14.
128. Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S. Cellular internalization and distribution of argininerich peptides as a function of extracellular peptide concentration, serum and plasma membrane associated proteoglycans. Bioconjug Chem 2008; 19:656-64.
129. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001; 276:3254-61.
130. Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 2007; 104:20805-10.
131. Yesylevskyy S, Marrink SJ, Mark AE. Alternative mechanisms for the interaction of the cell-penetrating peptides penetratin and the TAT peptide with lipid bilayers. Biophys J 2009; 97:40-9.
132. Ciobanasu C, Siebrasse JP, Kubitscheck U. Cell-penetrating HIV1 TAT peptides can generate pores in model membranes. Biophys J 2010; 99:153-62.
133. Schmidt N, Mishra A, Lai GH, Wong GC. Argininerich cell-penetrating peptides. FEBS Lett 2010; 584:1806-13.
134. Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta 2005; 1712:161-72.
135. + leukaemia cells. Biochem J 2007; 403:335-42.
136. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 2006; 20:1775-84.
137. Heng BC, Cao T. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody). Medical Hypotheses 2005; 6:1105-8.
138. Muller S, Zhao Y, Brown TL, Morgan AC, Kohler H. TransMabs: cell penetrating antibodies, the next generation. Expert Opin Biol Ther 2005; 5:237-41.
139. Anderson DC, Nichols E, Manger R, Woodle D, Barry M, Fritzberg AR. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide. Biochem Biophys Res Commun 1993; 194:876-84.
140. Zhao Y, Lou D, Burkett J, Kohler H. Chemical engineering of cell penetrating antibodies. J Immunol Methods 2001; 254:137-45.
141. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13:729-36.
142. Stein S, Weissb A, Adermannc K, Lazarovicid P, Hochmane J, Wellhöner H. A disulfide conjugate between anti-tetanus antibodies and HIV (37-72). Tat neutralizes tetanus toxin inside chromaffin cells. FEBS Lett 1999; 458: 383-6.
143. Chen BX, Erlanger BF. Intracellular delivery of monoclonal antibodies. Immunol Lett 2002; 84:63-7.
144. Zhao Y, Brown TL, Kohler H, Muller S. MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis. Apoptosis 2003; 8:631-7. (Pubitemid 37411747)
145. Cohen-Saidon C, Nechushtan H, Kahlon S, Livni N, Nissim A, Razin E. A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 2003; 102:2506-12.
146. Nakajima O, Hachisuka A, Okunuki H, Takagi K, Teshima R, Sawada JI. Method for delivering radiolabeled single-chain Fv antibody to the brain. J Health Sci 2004; 50:159-63. (Pubitemid 41289038)
147. Ohara-Imaizumi M, Nishiwaki C, Kikuta T, Kumakura K, Nakamichi Y, Nagamatsu S. Site of docking and fusion of insulin secretory granules in live MIN6 beta cells analyzed by TAT-conjugated anti-syntaxin 1 antibody and total internal reflection fluorescence microscopy. J Biol Chem 2004; 279:8403-8. (Pubitemid 38294733)
148. Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 2005; 65:2815-24. (Pubitemid 40490084)
149. 125I-labeled Fab fragment in rats. Bioconjug Chem 2006; 17:597-602.
150. Kameyama S, Okada R, Kikuchi T, Omura T, Nakase I, Takeuchi T, et al. Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats. Mol Pharm 2006; 3:174-80. (Pubitemid 43672253)
151. Chen BC, Erlanger BF. Cell cycle inhibition by an anti-cyclin D1 antibody chemically modified for intracellular delivery. Cancer Lett 2006; 244:71-5.
152. Theisen DM, Pongratz C, Wiegmann K, Rivero F, Krut O, Kronke M. Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies. Vaccine 2006; 24:3127-36.
153. Kameyama S, Horie M, Kikuchi T, Omura T, Tadokoro A, Takeuchi T, et al. Acid wash in determining cellular uptake of Fab/cell-permeating peptide conjugates. Biopolymers 2007; 88:98-107.
154. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging 2007; 34:368-77.
155. Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, et al. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 2008; 22:1237-45.
156. Poungpair O, Pootong A, Maneewatch S, Srimanote P, Tongtawe P, Songserm T, et al. A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus. Bioconjug Chem 2010; 21:1134-41.
157. Barka T, Gresik ES, Henderson SC. Production of cell lines secreting TAT fusion proteins. J Histochem Cytochem 2004; 52:469-77.
158. Koutsokeras A, Kabouridis PS. Secretion and uptake of TAT-fusion proteins produced by engineered mammalian cells. Biochim Biophys Acta 2009; 1790:147-53.
159. Shaw PA, Catchpole IR, Goddard CA, Colledge WH. Comparison of protein transduction domains in mediating cell delivery of a secreted CRE protein. Biochemistry 2008; 47:1157-66.
160. Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 2007; 117:148-62. (Pubitemid 46172502)
161. Nakayama K. Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997; 327:625-35.
162. Tikhonov I, Ruckwardt TJ, Berg S, Hatfield GS, David Pauza C. Furin cleavage of the HIV-1 Tat protein. FEBS Lett 2004; 565:89-92.
163. Flinterman M, Farzaneh F, Habib N, Malik F, Gaken J, Tavassoli M. Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 2009; 17:334-42.
164. Falnes PO, Wesche J, Olsnes S. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 2001; 40:4349-58.
165. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995; 3:783-91.
166. Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, Hemmi S, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol 2002; 158:1119-31.
167. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10:310-5.
168. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157:195-206.
169. Mie M, Takahashi F, Funabashi H, Yanagida Y, Aizawa M, Kobatake E. Intracellular delivery of antibodies using TAT fusion protein A. Biochem Biophys Res Commun 2003; 310:730-4.
170. Mie M, Mori K, Funabashi H, Kobatake E. Delivery of antibody-captured proteins into living cells using PTD-fused protein A. Biotechnol Lett 2006; 28:1209-14.
171. Albarran B, To R, Stayton PS. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells. Protein Eng Des Sel 2005; 18:147-52.
172. El-Sayed A, Futaki S, Harashima H. Delivery of Macromolecules Using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J 2009; 11:13-22.
173. Maxfield FR. Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultured mouse fibroblasts. J Cell Biol 1982; 95:676-81.
174. Erbacher P, Roche AC, Monsigny M, Midoux P. Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA lactosylated polylysine complexes. Exp Cell Res 1996; 225:186-94.
175. Ciftci K, Levy RJ. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int J Pharm 2001; 81-92.
176. Caron NJ, Quenneville SP, Tremblay JP. Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys Res Commun 2004; 319:12-20.
177. Wang H, Zhong CY, Wu JF, Huang YB, Liu CB. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J Control Release 2010; 143:64-70.
178. Hogset A, Prasmickaite L, Selbo PK, Hellum M, Engesaeter BO, Bonsted A, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004; 56:95-115. (Pubitemid 38045426)
179. Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999; 59:1180-3.
180. Maeda T, Kawasaki K, Ohnishi S. Interaction of influenza virus hemagglutinin with target membrane lipids is a key step in virus-induced hemolysis and fusion at pH 5.2. Proc Natl Acad Sci USA 1981; 78:4133-7.
181. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza hemagglutinin at the Ph of membrane-fusion. Nature 1994; 371:37-43.
182. Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T, et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 2005; 280:8285-9.
183. Lo SL, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008; 29:2408-14.
184. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278:585-90.
185. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 2007; 24:1977-92.
186. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 2003; 278:31192-201.
187. Cheung JC, Kim Chiaw P, Deber CM, Bear CE. A novel method for monitoring the cytosolic delivery of peptide cargo. J Control Release 2009; 137:2-7.
188. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol Rev 1984; 36:277-336.
189. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009; 61:953-64.
190. Rapoport M, Lorberboum-Galski H. TAT-based drug delivery system - new directions in protein delivery for new hopes? Expert Opin Drug Deliv 2009; 6:453-63.
191. Fotin-Mleczek M, Welte S, Mader O, Duchardt F, Fischer R, Hufnagel H, et al. Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J Cell Sci 2005; 118:3339-51.
192. Letoha T, Kusz E, Papai G, Szabolcs A, Kaszaki J, Varga I, et al. In vitro and in vivo nuclear factorkappaB inhibitory effects of the cell-penetrating penetratin peptide. Mol Pharmacol 2006; 69:2027-36.
193. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladriere L, et al. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochim Biophys Acta 2007; 1768:2222-34.
194. Mueller J, Kretzschmar I, Volkmer R, Boisguerin P. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem 2008; 19:2363-74.
195. Hetzel C, Bachran C, Tur MK, Fuchs H, Stocker M. Improved immunotoxins with novel functional elements. Curr Pharm Des 2009; 15:2700-11.
196. Rybak SM, Arndt MA, Schirrmann T, Dubel S, Krauss J. Ribonucleases and immunoRNases as anticancer drugs. Curr Pharm Des 2009; 15:2665-75.
197. Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dubel S. Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 2009; 9:79-95.
198. Wedekind JE, Trame CB, Dorywalska M, Koehl P, Raschke TM, McKee M, et al. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol 2001; 314:823-37.
199. Perier A, Chassaing A, Raffestin S, Pichard S, Masella M, Menez A, et al. Concerted protonation of key histidines triggers membrane interaction of the diphtheria toxin T domain. J Biol Chem 2007; 282:24239-45.
200. Hartley MR, Lord JM. Cytotoxic ribosome-inactivating lectins from plants. Biochim Biophys Acta 2004; 1701:1-14.
201. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, et al. Preparation of potent cytotoxic ribonucleases by cationization: Enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 2001; 40:7518-24.
202. Rodriguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF, Ribo M, et al. Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 2007; 120:1405-11.
203. Casellas P, Bourrie BJ, Gros P, Jansen FK. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 1984; 259:9359-64.
204. Heisler I, Sutherland M, Bachran C, Hebestreit P, Schnitger A, Melzig MF, et al. Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. J Control Release 2005; 106:123-37.
205. Bachran C, Sutherland M, Heisler I, Hebestreit P, Melzig MF, Fuchs H. The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure. Exp Biol Med 2006; 231:412-20.
206. Sehnert B, Burkhardt H, Nimmerjahn F, Pohle S, Wessels J, Vestweber D, et al. A Tissue-specific NFkappaB inhibitor ameliorates inflammatory joint diseases. Ann Rheum Dis 2010; 69:45.
207. Fuchs H, Bachran C, Li T, Heisler I, Dürkop H, Sutherland M. A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J Control Release 2007; 117:342-50.
208. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stöcker M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 3:370-6.
209. Rizk SS, Luchniak A, Uysal S, Brawley CM, Rock RS, Kossiakoff AA. An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells. Proc Natl Acad Sci USA 2009; 106:11011-5.